Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.56 +0.34 (+1.40%)

Streaming Delayed Price Updated: 3:37 PM EDT, Apr 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,433,394
Open	23.52
Bid (Size)	24.55 (200)
Ask (Size)	24.57 (300)
Prev. Close	24.22
Today's Range	23.52 - 24.99
52wk Range	13.53 - 36.44
Shares Outstanding	79,199,501
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

Today 10:32 EDT

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

April 01, 2026

From Beam Therapeutics

Via GlobeNewswire

Performance

YTD	-9.5%	-9.5%
1 Month	-14.4%	-14.4%
3 Month	-11.4%	-11.4%
6 Month	+1.8%	+1.8%
1 Year	+39.3%	+39.3%

More News

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

March 25, 2026

From Beam Therapeutics

Via GlobeNewswire

BEAM Stock In Focus As FDA Alignment Wins William Blair’s Praise ↗

January 12, 2026

Via Stocktwits

What's Going On With Beam Therapeutics Stock? ↗

February 24, 2026

Via Benzinga

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

February 24, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

February 24, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program

February 23, 2026

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Senior Vice President Sells 6,198 Shares for $216,933 ↗

February 01, 2026

Via The Motley Fool

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today ↗

January 29, 2026

Via Stocktwits

Top stock movements in today's session. ↗

January 12, 2026

Via Chartmill

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition

January 11, 2026

From Beam Therapeutics

Via GlobeNewswire

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

December 06, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics (BEAM) Earnings Transcript ↗

November 27, 2025

Via The Motley Fool

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

November 12, 2025

From Beam Therapeutics

Via GlobeNewswire

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

Via TokenRing AI

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Via Benzinga

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

November 04, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

November 03, 2025

From Beam Therapeutics

Via GlobeNewswire

WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗

October 20, 2025

Via Benzinga

Jefferies Initiates Beam Therapeutics with "Buy" Rating, Eyeing Promising Gene-Editing Pipeline and Upcoming Catalysts

October 09, 2025

Via MarketMinute

Jim Cramer Sees More Upside For Shopify, Likes CoreWeave's AI Moves ↗

October 08, 2025

Via Benzinga

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

Via MarketMinute

Frequently Asked Questions

Is Beam Therapeutics Inc. - Common Stock publicly traded?

Yes, Beam Therapeutics Inc. - Common Stock is publicly traded.

What exchange does Beam Therapeutics Inc. - Common Stock trade on?

Beam Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Beam Therapeutics Inc. - Common Stock?

The ticker symbol for Beam Therapeutics Inc. - Common Stock is BEAM on the Nasdaq Stock Market

What is the current price of Beam Therapeutics Inc. - Common Stock?

The current price of Beam Therapeutics Inc. - Common Stock is 24.56

When was Beam Therapeutics Inc. - Common Stock last traded?

The last trade of Beam Therapeutics Inc. - Common Stock was at 04/02/26 03:37 PM ET

What is the market capitalization of Beam Therapeutics Inc. - Common Stock?

The market capitalization of Beam Therapeutics Inc. - Common Stock is 1.95B

How many shares of Beam Therapeutics Inc. - Common Stock are outstanding?

Beam Therapeutics Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.